Multi-million-euro strategic collaboration to develop RORyt inhibitors

A strategic global collaboration focusing on the development and commercialization of a novel RORyt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis has been announced.

As part of the agreement, the Spain’s largest drugmaker Almirall (ALM: MC) and a Danish unit of the Sweden listed Nuevolution (NUE: STO) will also establish a research collaboration for the identification of additional RORyt inhibitors, with an exclusive option for Almirall to use within the dermatological field and with the optional use outside the field of collaboration for Nuevolution.

Almirall will be responsible for funding of any further research as well as pre-clinical, clinical, regulatory and commercial activities. Nuevolution will be responsible for funding of any of its own research.